Clinical Studies
Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
NeuroOphthalmology
Obesity/Weight Management
Women's Health
Other
Special Features
Advances/Research
| Principal Investigator: | Nicholas H.E. Mezitis, MD | |
| Time frame of study: | Ongoing | |
| Time frame of participation: | 14 months | |
| Number of participants needed: | Open | |
| Location of Study: | St. Luke's-Roosevelt Hospital 1111 Amsterdam Avenue Room WH1006 |
|
| Contact Name, Number & Email: | Felicia Stein or Eleanor Bauza at 212-523-4171 |
Summary:
A multicenter, double-blind, placebo-controlled, parallel-group study of the effects of Oral Zopolrestat in Normotensive, Type 1 Diabetics with incipient Nephropathy (Microalbuminuria).
Zopolrestat is a novel medication which interferes with protein glycosylation and may delay and prevent the onset of vascular complications in diabetes mellitus.
Criteria for Participation:
Participants must be between the ages of 18 and 45 with a diagnosis of type 1 diabetes for more than 5 years. Women of child-bearing potential must be practicing a medically-approved method of birth control.
Benefits and/or Compensation:
Persons who qualify will receive free physical examinations, laboratory tests, electrocardiograms, kidney function tests, a blood glucose meter and supplies, medical supervision and a stipend.